Eligibility Criteria and Treatment Strategies
MAY
We considered all cohort participants who were HIV treatment-naïve after 1 May 2008 (when the first INSTI raltegravir was licensed in Switzerland) and who initiated ART thereafter. Individuals who started unknown ART, those who initiated ART including maraviroc or enfuvirtide, and individuals who had an HIV RNA at treatment start <50 cp/mL were excluded because those individuals may not have been treatment naïve. INSTI starters included all participants who received any INSTI-containing ART as first treatment, regardless of whether other ART components (eg, NNRTI, PI) were coadministered.